Subscribe to Life Science Success for cutting-edge insights, expert interviews, and a vibrant community. Your subscription fuels our mission and keeps you at the forefront of life sciences.
In this episode of Life Science Success, my guest is Dr. Helen Torley. Dr. Torley is the President and CEO of Halozyme. Halozyme's innovative and disruptive solutions provide new therapeutic options that could significantly improve the patient...
In this episode of Life Science Success, my guest is Dr. Helen Torley. Dr. Torley is the President and CEO of Halozyme. Halozyme's innovative and disruptive solutions provide new therapeutic options that could significantly improve the patient experience by changing how treatments are delivered.
Please check out our Life Science Success Resources. You will find tools that will support growing companies and books for authors I have interviewed.
CEO
Helen Torley
M.B. Ch. B., M.R.C.P.
President and Chief Executive Officer
Dr. Helen Torley is the President and CEO of Halozyme. Halozyme's innovative and disruptive solutions provide new therapeutic options that could significantly improve the patient experience. Halozyme changes how treatments are delivered. When using Halozyme’s ENHANZE drug-delivery technology, the treatment time for a drug to treat the most common form of blood cancer is cut from a four to six hours IV infusion to an approximately 5-minute subcutaneous delivery.
Dr. Torley brings extensive commercial and business experience as well as an extensive knowledge of the biotechnology industry. Dr. Torley joined Halozyme in January 2014 as President and Chief Executive Officer. Throughout her career, Dr. Torley has led several successful product launches, including Kyprolis®, Prolia®, Sensipar®, and Miacalcin®. Prior to joining Halozyme, Dr. Torley served as Executive Vice President and Chief Commercial Officer for Onyx Pharmaceuticals (Onyx) from August 2011 to December 2013. In this role she was responsible for the successful launch of Kyprolis in the US and led the development of Onyx’s commercial capabilities in ex-U.S. markets and in particular, in Europe. She also oversaw the development and commercial collaboration with Bayer on Nexavar® and Stivarga®.
Prior to Onyx, Dr. Torley spent 10 years in management positions at Amgen Inc., most recently serving as Vice President and General Manager of the U.S. Bone Health Business Unit from 2009 to 2011 and the U.S. Nephrol… Read More
In this episode of Life Science Success, host Don Davis has a conversation with Dr. Mohit Jain, a physician scientist with extensive experience in physiology, biomedicine, and mass spectrometry. Dr. Jain shares his unique journey from clinical...
This week on Life Science Success, we are thrilled to welcome back Elizabeth Smalley as our guest. Elizabeth is the VP, Product Management, Data & Analytics at ArisGlobal, where she plays a pivotal role in steering the company’s strategic...
In this episode of Life Science Success, my guest is Cristian Massacesi MD. Cristian is the Chief Medical Officer & Oncology Chief Development Officer at AstraZeneca. In the interview, we will discuss his start in oncology, his career...
This week on the Life Science Success podcast, my guest is Thomas Farb-Horch. Thomas is the CEO of Thrive Bio. He has been involved in the founding of 18 pharmaceutical, biotech, medtech, software, and AI companies, 7 of which have …
